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INTRODUCTION 
Systemic sclerosis is a chronic autoimmune connective tissue 
disease of unknown etiology involving multiple systems. It is 
characterized by significant dysfunction of the microvasculature, 
immune system and connective tissue.  
The currently used classification of Systemic Sclerosis is by 
the extent of skin involvement
1
. The extent of skin disease correlates 
with the disease course. Though many internal organs are involved, 
lung involvement is the major cause of morbidity and mortality in 
SSc. While some studies regard skin involvement as a surrogate 
marker for pulmonary involvement, there are studies that have 
shown  improvement of sclerosis occurring spontaneously or as a 
result of treatment  and therefore it does not reflect the pulmonary 
fibrosis. In addition several cutaneous features have been found to 
be associated with clinical and serological manifestations in 
systemic sclerosis. In a recent study
2
 elevated serum level of MMP-
12 correlated with the severity of skin fibrosis and activity of 
interstitial lung disease in systemic sclerosis, suggesting the 
common pathogenesis between them. So the skin can be useful 
marker for early diagnosis and to assess pulmonary involvement.  
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AIMS AND OBJECTIVES 
 To study the skin and pulmonary manifestations in Systemic 
Sclerosis.  
 To study the correlation of the clinical, pathological, 
immunological features of skin and pulmonary involvement 
in Systemic Sclerosis. 
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REVIEW OF LITERATURE 
Systemic Sclerosis(SSc) is a chronic autoimmune disease of 
unknown etiology. It can affect the skin and other internal organs.  
It has a chronic course seen commonly in women and is 
heterogenous in its clinical manifestations. The hall mark of SSc is 
the involvement of the skin which becomes thick and indurated 
(Scleroderma). 
Scleroderma spectrum disorders consists of 
 Systemic sclerosis. 
 Localized scleroderma. 
 Infiltrative disorders (Amyloidosis, Scleromyxedema, 
Scleroderma of Buschke). 
 Inflammatory conditions (overlap connective tissue disease, 
eosinophilic fascitis, chronic graft versus host disease, 
sarcoidosis). 
 Metabolic disorders (myxedema, porphyria, cutaneous  tarda, 
congenital prophyria, acromegaly). 
  4 
Diffuse and limited cutaneous forms are the 2 major subsets 
of SSc. Diffuse cutaneous type has progressive course and organ 
failure occur within 5 years of onset. Whereas in limited cutaneous 
type , major organ involvement occurs later in the disease course. 
PRELIMINARY ACR CLASSIFICATION CRITERIA FOR 
SYSTEMIC SCLEROSIS   
Preliminary ACR classification criteria
3
 for Systemic 
Sclerosis  consists of 1 major and 3 minor criteria.  
Major criteria 
Scleroderma proximal to the metacarpophalangeal joints. 
Minor Criteria 
1. Sclerodactyly. 
2. Digital pitting scars or loss of finger pad substance. 
3. Bibasilar pulmonary fibrosis. 
Systemic Sclerosis should satisfy 1 major and 2 minor 
criteria. 
Classification based on skin involvement is  
1) Diffuse cutaneous SSc: Skin thickening widespread, 
involving trunk, proximal extremities, distal extremities and 
and face. 
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2) Limited Cutaneous SSc: Skin thickening only distal to elbow 
and knees, face and neck may be involved. 
3) CREST Syndrome: Subset of limited cutaneous SSc and 
consists of calcinosis, Raynauds phenomenon, sclerodactyly, 
esophageal dysmotility and telangiectasias. 
4) Overlap SSc: Features of SSc and its skin changes present 
along with features of another connective tissue disease like 
SLE, RA or Myositis. 
5) SSc sine sclerosis: Characteristic internal organ involvement, 
serologic abnormalities and Raynaud‟s Phenomenon are 
present without any skin involvement. 
EPIDEMIOLOGY 
SSc is a sporadic disease and there is variation in the 
incidence and prevalence in different geographic areas.  The study 
by Mayes et al
4
, the incidence ranges from 9 to 19 cases per 
million/ year and the prevalence rates are 28 to 253 cases/ 1 
million/ year in the united states.  
GENDER 
It is most common in women than men, with female to male 
ratio ranging from 4:1 to 6:1
5
. Female preponderance may be due to 
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hormone use or pregnancy, microchimersim or preferred skewing of 
X chromosome inactivation, towards one parental source. 
Microchimerism occurs normally during pregnancy due to cell 
transfer from fetus to mother resulting in genetically distinct small 
populations
6
. These cells persist through decades and may 
contribute to the pathogenesis of autoimmune disease. 
ETIOLOGY 
In SSc, the etiology is unknown. 
Genetic factors contribution in SSc is uncertain. Disease 
concordance in both mono and dizygotic twins are similar. Study by 
Arnett et al
7
 showed the risk of systemic sclerosis with positive 
family history was 1.6% while in general population were 0.026%. 
Weak association with DRB1 *11 and DRB1 * 0301 were shown in 
early studies. Single nucleotide polymorphism in PTPN 22 & IRF5 
have been associated with SSc
8
. By European / US GWAS analysis 
showed there is a role of the MHC, IRF5 and STAT4 gene regions 
as genetic risk factor for SSC. CD 247 (Locus which codes for TCR 
subunit), CDH7, IRF4 are additional genetic loci identified by 
GWAS. There is altered gene expression in the skin of the two 
subtypes of SSc. 
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Diffuse cutaneous SSC can be subdivided into 2 groups based 
on expression of distinct gene clusters which are “Signatures” 
indicating proliferation or inflammation
9
. The two subgroups are 
stable overtime, suggesting heterogenecity rather than different 
stages of same process. 
INFECTIOUS AGENTS 
Human cytomegalovirus, human parvovirus B19 infection are 
implicated as potential triggers
10
. Presence of antibodies directed 
against hCMV derived proteins epitopes UL 83 and UL 94, have 
been detected in the serum of SSC patients
11
. Anti topoisomerase1 
antibody cross reacts with hCMV derived protein, so molecular 
mimicry may be a mechanism linking hCMV infection and SSc. 
ENVIRONMENTAL AGENTS, DRUGS AND RADIATIONS 
Toxic oil syndrome, due to ingestion of contaminated 
rapeseed cooking oils, contaminated L-tryphophan dietary 
supplements, exposure to certain gadolinium containing radiology 
imaging dyes produced scleoderma like skin induration with or 
without multi-system involvemen
12
.  
Exposure to silica, heavy metals, mercury, organic chemicals 
like vinyl chlorides, benzene, toluene are implicated in SSc. 
Cigarette smoking does not appear to have a role in etiology of SSc. 
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Drugs implicated in SSc like illness are bleomycin, 
Pentazocine, Cocaine, Fenfluramine etc. Radiation given for 
malignant neoplasms has been linked with new onset SSc as well as 
exacerabation of pre-exsiting SSc
 13
. 
PATHOLOGY 
The pathologic hallmarks of SSc are a non inflammatory 
proliferative / obliterative vasculopathy involving small arteries  
and arterioles in the multiple vascular beds along with interstitial/ 
vascular fibrosis in the skin, lungs and other internal organs.  
Vasculopathy 
The primary pathogenetic event in SSc is vascular injury and 
activation. Histopathologic evidence and clinical signs of 
vasculopathy occur before fibrosis and other disease 
manifestation
14
. 
Initial endothelial injury causes endothelial cell activation 
and dysfunction. The increase in adhesion molecules, endothelial 1 
production result in impaired vasodilation, increased 
vasoconstriction and lead to endothelial dysfunction. This results in 
vascular wall remodelling and vascular obliteration finally leading 
to tissue hypoxia and fibroblast activation.  
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These is bland intimal proliferation of the small and medium 
sized arteries and expansion of the intimal layer. Vasculitis or 
deposition of immune complex on the vessel wall is rare. The 
clinical signs of vasculopathy are Raynaud‟s Phenomenon, 
cutaneous telangiectasia, digital pit formation, nail fold capillary 
alteration, pulmonary hypertension, scleroderma renal crisis and 
gastric antral vascular ectasia. 
As the disease progresses fibrosis deposition and perivascular 
fibrosis occur, leading to obliterative vasculopathy and chronic 
tissue hypoxia
15
.  
Tissue Fibrosis 
Excessive accumulation of type-I collagen along with other 
fibrillar collagen, fibronectin, elastin, proteoglycans and COMP 
results in tissue fibrosis. This process disrupts the tissue and organs 
and contributes to progressive dysfunction and organ failure. The 
most prominently affected organs are skin, lungs, GIT, heart, 
perifascicular tissue around the muscle, and tendon sheaths.  
ORGAN SPECIFIC PATHOLOGIC FINDIGNS 
Skin 
Fibrosis of the skin causes marked expansion of dermis and 
obliteration of sweat glands, hair follicles and other skin 
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appendages. Collagen fiber accumulation is prominent in the 
reticular dermis. With progression, the subjacent adipose layer is 
gradually involved with entrapment of fat cells. In the early stages, 
there is deep dermal inflammatory cells composed mainly of T 
lymphocytes, monocytes and less commonly eosinophils and mast 
cells. The  myofibroblast, which are mesenchymal contractile cells  
are increased and they play a major role in fibrogenesis. As time 
progress, the skin undergoes atrophy with epidermis thinning and 
effacement of rete pegs. Decrease in dermal capillaries contribute 
to tissue hypoxia which can occur even in apparently normal skin 
of patients with Scleroderma. 
 Study by Jens T Van Pret et al
16
 revealed that the mean 
epidermal thickness, myofibroblast score and hyalinised collagen 
score were linked to local clinical skin involvement and correlated 
well with the local skin score. Myofibroblasts and intima 
proliferation of the deep arterioles or parakeratosis in skin biopsy 
are useful specific diagnostic markers for SSc but with low 
sensitivity. 
Biochemical analysis show that the fibrotic dermis have 
major fibrillar collagens, type I and III collagens similar to the 
normal skin. But type 7 collagen, minor nonfibrillar collagen, 
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which is normally restricted to the dermal epidermal basement 
membrane were present in excess throughout the lesional dermis. 
Enzymes mediating post translational collagen modification like 
lysyl hydroxylase (PLOD2) is increased and they contribute to 
densely sclerotic nature of fibrotic dermis
17
. 
LUNGS 
The earliest change in patients with scleroderma with 
interstitial lung disease are patchy lymphocytes and plasma cell 
infiltration of the alveolar walls. In this stage, alveolar lavage fluid 
contains inflammatory leukocytes and cells of the polarised Th2 
immune response. As disease progresses, lung inflammation 
subsides with interstitial fibrosis and vascular damage will 
predominate, though both make coexist within the same lesion. 
In pulmonary fibrosis local accumulation of collagens and 
other tissue proteins results in the expansion of the alveolar 
interstitium. Non Specific Interstitial Pneumonitis (NSIP) is the 
most common histologic pattern characterised by mild to moderate 
interstitial inflammation, type 2 pneumocyte by hyperplasia and 
early uniform distribution of fibrosis. Usual Interstitial Pneumonia 
(UIP) in less common pattern in SSc -ILD with features of patchy 
fibrosis and carries a worse prognosis when compared with NSIP 
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pattern. In 2 studies, NSIP occurred in 78% of 80 patients and 68% 
of 19 patients respectively
18
. Fibrotic NSIP was seen in most 
patients, while cellular NSIP occurred in one quarter of the patients 
within the NSIP pattern. The UIP pattern occurred in 8% and 26% 
of patients in the 2 studies
19
. 
PATHOGENESIS OF FIBROSIS 
The pathogenesis of SSc is complex and not completely 
understood. A holistic approach must integrate the 3 cardinal 
features of SSc (i) Vascular injury and damage (2) activation of the 
innate and adaptive autoimmunity (3) generalized fibrosis. 
Upregulated adhesion molecules VCAM-1 and ICAM-1 in 
SSc skin along with MHC Class-II provide a cognate endothelial 
interaction with T Cells.. 
The study in the UCD 200/ 206 chicken model of scleroderma 
showed presence of dermal endothelial cell apoptosis in dermal 
vessels of early SSC patients. But recent study
22
, questioned the 
importance of apoptosis in SSC vasculopathy due to lack of caspase 
3 staining. 
Upregulation of 2c adrenoreceptors during stress results in 
exaggerated cold induced vasospasm, Raynaud‟s Phenomenon. The 
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resulting ischemic reperfusion injury has profound effects on 
vascular cells. Hypoxia induces expression of ET-1 (Endothelin-1), 
VEGF and PDGF, inhibiting eNOS and enhances endothelial cell 
apoptosis. 
Increased plasma ET-1 levels are associated with diffuse 
cutaneous subset, Pulmonary Arterial Hypertension (PAH), 
Pulmonary fibrosis and scleroderma renal crisis. 
ET-1 plays a important role in the vascular pathology of SSc 
and is evidenced in the BUILD-2 study
23
 by the efficacy of the dual 
endothelin receptor antagonist bosentan in preventing ischemic 
digital ulcers and improvement of PAH. There is increased ET-1 
and ET-1 receptor expression in the skin and lung tissue of SSc 
patients as ET-1 enhances type-I and III collagen synthesis, 
fibroblast proliferation, while decreasing expression of MMP-1. 
There is activation of the innate and adaptive arms of the 
immune system in early SSc with prominent autoimmunity. 
Activated CD4 and CD8 T lymphocytes, monocytes/ macrophages, 
eosinophils, mast cells and natural killer cells are seen in 
perivascular region of the skin, lung and other affected organ. They 
are detected even before the occurrence of fibrosis. 
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The skin severity and progression correlates with the extent 
of lymphocytic tissue infiltrates. There is skewing of immune 
response toward a Th 2 pattern as Th2 cytokines like IL-4, IL-5, IL-
13 are pro fibrotic and stimulates TGF , collagen synthesis and 
myofibroblast transdifferentiation. SSc skin biopsy specimens with 
clones of CD4 + T cells shows Th2 cytokines profile, similarly 
alveolar CD8 + T cells from SSc patients shows revealed Th 2 
cytokine production. The Th 2 predominance predicts decline in 
lung function. 
 CELLULAR DETERMINANTS OF FIBROSIS 
Cellular determinants of fibrosis are fibroblast, 
myofibroblast, pericytes and fibrocytes. 
Inappropriate fibroblast activation causing exaggerated ECM 
accumulation and remodelling is the fundamental pathogenetic 
mechanism for the fibrosis in SSc. 
Myofibroblasts arise from fibroblasts in response to TGF  
and express smooth muscle actin, synthesize collagen, MMP 
inhibitors and ECM components
20
. They are great source of TGF  
in the fibrotic response. 
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Pericytes are mesenchymal cells present normally in the wall 
of microvessels and maintain vascular homeostasis. In SSc, 
activated pericytes differentiate into fibroblasts and myofibroblasts 
thereby linking fibrosis and microvascular injury. 
Fibrocytes are CD 34+ mesenchymal cells derived from bone 
marrow and can synthesize collagen and present antigen. 
MOLECULAR DETERMINANTS OF FIBROSIS 
Though there are many potent mediators of tissue fibrosis, 
transforming growth factor 1 (TGF ) has received importance as 
a very potent profibrotic factor and master regulator of physiologic 
and pathologic fibrosis. Studies have shown upregulated expression 
of TGF 1 and TGF 1 ligand in the skin and lungs of SSc patients.  
TGF  is secreted by platelets, T-Cells, monocytes/ 
macrophages as a latent complex which is activated by proteolytic 
enzymes, integrin and thrombospondin. TGF  binds to the specific 
surface receptors and trigger intracellular signal transduction 
leading to induction of target genes
21
. TGF  signalling in 
fibroblasts is by both the Smad (canonical) pathway and non Smad 
pathway which involve protein kinases (MAP kinases, JNK, focal 
adhesion kinase FAK  and non receptor tyrosine kinase CAbl).  
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Egr-1 is a DNA transcription factor induced at sites of acute 
injury and it increases collagen gene expression and production of 
TGF . 
Peroxisome proliferator- activated receptors-  a nuclear 
steroid hormone receptor and transcription factor in adipogenesis is 
reduced in SSc, lesional skin biopsies and lung. Thereby suggesting 
that PPAR-  has a role in preventing excess fibrosis. 
Other key growth factors that have been implicated in the 
pathogenesis are platelet derived growth factor PDGF, connective 
tissue growth factor (CTGF), chemokine monocyte chemoattractant 
proteins MCP-1 and MCP-3. Chemokine expression, PDGF 
receptor and ligand expression, TNF  expression occur early in the 
pathogenesis of scleroderma. 
AUTO ANTIBOIDES 
Autoantibodies can be detected in nearby all patients with 
SSc but their direct role in the pathogenesis is not well established. 
The pathogenetic autoantibodies implicated in tissue damage in 
SSc are antiendothelial cell antibodies (AECA) antifibroblast, 
anticollegenase, anti PDGF receptor and antifibrillin 1 antibodies. 
AECA play an important role in endothelial cell apoptosis, one of the 
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pathogenic events in SSc. Ahmed et al
24
, found AECA patients in 
both LcSSc and  dcSSc subtypes. 
Chizzolini et al
25
, detected antifibroblast antibodies in 58% of 
SSc patients with a greater prevalence seen in dcSSc. 
The nuclear autoantibodies targeting antitopoisomerase I 
(also known as Scl-70), centromere proteins (most consistent is 
CENP-B), RNA polymerase I and III and nucleolar proteins (like 
U3, fibrillarin) have specific associations with disease subsets and 
organ manifestations. The nuclear autoantigens become targets by 
exposing “neoepitope”, which are antigenic structure not previously 
recognised by the immune system.  
Fragmentation of  topoisomerase I results in exposure of 
cryptic epitopes and makes the peptide immunogenic. Other 
mechanisms of autoantibodies generation in SSc is molecular 
mimicry after viral infection, chronic B cell hyperreactivity, 
increased expression of autoantigenic peptides. 
Recent data suggested a role of autoantibodies in innate 
immunity, as evidenced by TLR-7 response in sera of SSc patients 
containing antitopoisomerase-I. 
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SCL7O is a 70 KDa autoantigen seen more commonly in 
diffuse cutaneous SSc but it may occur in limited cutaneous SSc 
also. It is prevalence is 15-20% in SSc patients. 
Antitopoisomerase-I was associated with pulmonary fibrosis, 
increased mortality in some studies. In one study
26
, Scl 70 
correlated with the presence of renal vascular damage as measured 
by Doppler ultrasonography. Recently the EUSTAR compared the 
frequency of organ manifestations according to presence of 
antitopoisomerase-I or anti CENP in a cohort of 2000 ANA positive 
patients
27
. The study confirmed previous associations, in addition 
there was increased frequency of musculoskeletal complaints, 
cardiac disturbances and proteinuria among anti topo I positive 
patients. Titres of topo-I have been linked to MRSS disease activity 
and presence of flexion contractures. In vitro studies provide a 
possible pathogenic role of topoisomerase-I by the evidence of 
topo-I auto antibodies binding to fibroblast cell surfaces. 
Anti centromere autoantibodies (ACA) are found in 20-30% 
of SSc patients and are most commonly associated with LcSSc, 
calcinosis, ischemic digital loss and pulmonary hypertension
28
. Anti 
CENPs can be detected by IIF, ELISA and line immunoassay. 
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Pulmonary fibrosis is negatively associated with ACA. The 
EUSTAR found ACA linked to increased time lag to overt clinical 
disease, less musculoskeletal and myocardial involvement and a 
high risk of intestinal symptoms and hypertension. 
Antibodies to polymyositis /Scl autoantigen is seen in 24% of 
polymyositis/ SSc overlap and 3% of SSc patients. Recent study
29
 
showed that PM/Scl is cleaved during apoptosis raising the 
possibility that fragmentation of protein leads to loss of 
immunogenic tolerance to the autoantigen. 
Antifibrillarin (anti U3 ribonucleoprotein) are directed 
against protein components of small U3, nucleolar RNP complex 
and are associated with dCSSc, male gender, increased internal 
organ involvement. 
RNA Polymerase I and II autoantibodies are highly specific 
for SSc and found  to be associated with dcSSc, renal crisis and 
decreased survival
30
. 
Th/To antibodies are directed against the ribonuclease P 
complexes and ribonuclease mitochondrial RNA processing 
subunits. They are seen in 2-5% of SSc patients and are associated 
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with increased severity of pulmonary fibrosis, decreased survival, 
milder cutaneous involvement and SSc sine scleroderma
31
. 
Anti Ku antibodies bind to nucleus and nucleolar proteins of 
interphase cells and have been detected in 1-14% of patients with 
SSc. 
The small nuclear ribonucleoproteins (SnRNPs), are uridine 
rich RNA and involved in DNA gene transcuption of mRNA. Study 
by Asano et al identified U1 RNA antibodies in 61% of SSc 
patients and observed that these antibodies may be marker for 
development of pulmonary fibrosis. 
Anti histone auto antibodies occur in 16-29% SSc patients 
and were associated with pulmonary fibrosis, renal and cardiac 
involvement and increased mortality. 
Expression of both antihistone antibodies and ACA were 
associated with severe pulmonary and vascular disease.  
CLINICAL FEATURES 
SKIN 
Skin involvement is the cardinal feature of SSc, it develop 
initially in the fingers and hands. The common early cutaneous 
manifestation is the non pitting edema of fingers, followed by skin 
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thickening and disabiling sclerosis of the fingers. In limited subset, 
patients have skin changes confined to face, neck and distal 
extremities (below the knees and elbows). The skin involvement is 
usually preceeded by Raynaud‟s Phenomenon and different patterns 
can occur at presentation. 
In diffuse SSc skin involvement in the hands, forearms, arms, 
chest, abdomen, thighs, legs and feet is seen. 
The changes are more consistent in diffuse SSc with initial 
edema of soft tissue of hands, legs followed by skin thickening, 
dermal fibrosis and sclerosis. 
As the sclerosis is progressing proximally the advancing edge 
of the involved skin is identifiable. 
Then the skin over the trunk, upper arms and thigh are 
involved. In early stage of DcSSc proximal skin involvement may 
be absent and appear like limited cutaneous type with only distal 
skin thickening. However over 2 years of disease course skin 
involvement of the trunk and proximal extremities occur.  
Thus, it decreases the reliability to classify patient as limited 
subset within the initial 2 years of onset of skin involvement.  
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There are 3 phases of skin changes, namely early, established 
and late. 
EARLY PHASE 
It is the initial inflammatory and edematous phase presenting 
as puffiness of hands and feet as the only feature thereby making a 
diagnosis difficult. This phase may last for 12-18 months.  
ESTABLISHED PHASE 
The skin becomes firm, taut, hidebound especially proximal 
to the MCP joints and adherent to deeper structures permitting a 
definite diagnosis of SSc. It is a longer phase with progressive skin 
fibrosis. Barnett‟s sign is the ridging of skin on the neck and is seen 
both limited and diffuse types. Skin thickening in the face and 
perioral region produces typical facial features associated with SSc 
like beak shaped nose, reduced aperture of the mouth (microstomy), 
radial furr owing around the mouth and finally expressionsless, 
“mauskopf” (mask like) facies. Fibrosis and atrophy of mandible 
results in gum and lips retraction causing front teeth to appear 
prominent.  
In this phase, the skin may be coarse, dry and pigmented. 
There is thinning of epidermis, decreased sweating, hair growth 
ceases and skin creases disappear. 
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Skin pigmentation, changes of both hypo and hyper 
pigmentation occur in the early inflammatory and progressive 
fibrosis phase. Areas of depigmentation occur over scalp, chest, 
upper back, pretibial, dorsum of hand and other pressure areas. 
These hypopigmented areas give the skin a “salt and pepper” 
appearance due to the perifollicular sparing of pigment loss. 
LATE PHASE 
After 2 years of disease duration, skin softening occurs. 
Secondary epithelial structures recover and regrowth of hair in the 
forearm is an early feature of skin softening. Skin will appear 
clinically normal over the trunk and upper area.  
MODIFIED RODNAN SKIN SCORE(MRSS) 
Rodnan pioneered a semiquantitative skin score to measure 
skin thickness that correlated with skin biopsy specimen weight and 
reflected the increased collagen content
32
. The original score had 26 
areas, 0-4 grading with range of 0-104. This score was subsequently 
simplified as modified Rodnan skin thickness score (MRSS). Skin 
thickness is assessed by palpation of 17 areas (Figure) and rated by 
scores from 0 to 3 in each areas with range 0-51. 
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Modified Rodnan Skin Score: 17 Sites to be assessed 
 
0- Normal skin. 
1- Mild skin thickening. 
2- Definite (established) thickening without fixation to 
deeper tissues. 
3- Hide bound skin/ severe thickening with fixation to deep 
tissues. 
Study by Furst DE et al, found MRSS as an accurate 
reflection of skin biopsy thickness in systemic sclerosis with good 
reliability and sensitivity to changes
33
. 
Using skin score data of patients, Steen and Medsger et al 
found MRSS, provided a surrogate measure of disease severity and 
had prognostic value, especially in dcSSc
34
. Patients with highest 
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peak skin score were least likely to improve and experienced 
significantly severe organ involvement. 
In early diffuse systemic sclerosis trial
35
 reported that a high 
baseline MRSS was associated with baseline cardiac involvement 
and predicted increased mortality and scleroderma renal crisis.  
The skin score greater or equal to 15 at the entry was 
associated with greater risk of early fatal renal and cardiac 
complications. 
In a prospective study of Ketanserin Vs placebo in SSc they 
found a strong correlation between MRSS and dry and wet weights 
of forearm skin biopsy. In this study the wet weight was higher in 
the DcSSc biopsy, thereby supporting the usefulness of MRSS to 
differentiate the SSc subtypes. 
A recent clinicopathological study
37
 showed MRSS correlated 
with histological extent of skin fibrosis as well as the TGF  
signalling in SSc fibroblasts (as measured by the increased smad3 
phosphorlyation levels). Thus MRSS is well validated and reflects 
the underlying pathogenesis of SSc. 
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Novel tools to assess the skin involvement are durometer , 
high frequency ultrasound, vestometer and elastometry. 
Durometer are hand held device that can be used to objectively 
measure skin thickening and hardening. Merkel et al
38
 demonstrated 
that the durometer measurements are reliable, valid and showed 
better sensitivity compared to MRSS. In the recent study
39
  
durometer scores correlated well with MRSS scores of fingers, 
hands, forearm, upper arm, thighs and feet, but poorly correlated 
with MRSS at the chest, abdomen and lower legs. 
A recent novel portable device, the electronic tonometer, to 
assess the skin hardness by measuring deformation produced by a 
known weight or force was used by M.Dugar et al
40
. They found 
skin hardness assessed by the device correlated well with the total 
MRSS, in addition it was able to detect minor changes.  Other 
cutaneous manifestations are digital ulcers, digital pitted scars, 
cutaneous telangiectasia and calcinosis. 
DIGITAL ULCER 
Digital ulcers is a significant clinical problem seen in 40-50% 
of SSc patients
41
. Significant vasopasm, digital vasculopathy, 
dermal fibrosis, epidermal atrophy and local trauma are risk factors 
  27 
for digital ulceration in SSc
42
. Digital ulcers occur at fingertips, 
finger creases, and less commonly on the toes, causing pain and 
functional impairment. Chronic ulcers have 15% complication rate, 
which include infection, gangrene, osteomyelitis and amputation. 
One amputation increase the chance of further amputations by 1-2% 
in the next 6-12 months. 
In a study to detect possible risk factors in SSc patients with 
digital ulcers, possible association between digital ulcers with PAH 
was postulated
43
. The digital ulcer and PAH have similar 
vasculopathy changes of fibrotic intimal hyperplasia, adventitial 
fibrosis and decreased arterial lumen. Studies using German 
Network for SSc and French Itiner AIR sclerodermic registry had 
identified association of digital ulcers with male sex, Scl 70 
antibodies
44
 and early age at onset
45
. 
Digitals ulcers were found to have negative impact on the 
physical and mental components of quality of life
46
. 
Digital ulcers can be active and healed ulcers. In active 
ulcers, there is denuded areas with defined border loss of 
epithelialization epidermis and dermis loss. Healed ulcers are 
characterized by complete epithelialization of the ischemic ulcer.  
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DIGITAL PITTING SCARS 
Digital pits is a part of ACR criteria for SSc and represent 
areas of ischemic insult. It need not be preceded by digital ulcers. 
They appear as pinhole sized depression with hyperkeratosis.  
Digital pitted scars were seen in 39% of SSc patients and was 
found to associated with Raynaud‟s Phenomenon, skin thickening 
and joint disease
47
. 
Disease duration were not associated with the numbers of scars. 
Raynaud‟s Phenomenon occurs in more than 95% of SSc 
patient. In primary Raynaud‟s Phenomenon digital vasopasm is 
reversible without progression to tissue injury. While in SSc 
patients with Raynaud‟s Phenomenon progress to digital ischemia 
resulting in digital ulcers, digital pitted scars and even gangrene. 
Herrick et al showed that the digital ischemia in SSc is due to 
abnormalities in neuroendocrine mechanism, vasculature structure 
(both microvessels and digital arteries), intra vascular factors and 
oxidative stress
48
. 
In systemic sclerosis, there is exaggerated generalized 
vasospastic tendency clinically presenting as Raynaud‟s 
Phenomenon as shown by early digital arterial closure after cold 
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stimulation and inadequate vasodilatory response to heat. It is not 
only seen in the extremities, but can occur in internal organs
49
.  
It may be the initial event in the pathophysiology of SSc. 
Clinically it is characterized by typical tricolour  changes primarily 
in the acral body parts. There is sudden pallor of digits of fingers 
(white ischemia) followed by reactive erythema (red hyperemia) after 
rewarming. In severe attacks ischemia followed by cyanosis prior to 
hyperemia and is associated with pain or dysesthesia. 
Vascular changes in systemic sclerosis may at least partially 
reflect vascular alterations in other organs suggesting a general 
pathomechanism in SSc
50
. 
Raynaud‟s Phenomenon were considered to be associated 
with a vascular form of pulmonary involvement and PHT. In study 
by Mukerjee et al, pulmonary vasospasm response to peripheral and 
central cold challenge did not contribute to persistence of PAH on 
SSc patients. 
Structural vascular abnormalities occur in microcirculation 
and digital arteries in SSc patients. In the microvasculature, there is 
decrease in the number of capillaries, abnormal capillaries often 
with dilated loops, hemorrhages and capillary drop outs. 
  30 
RP together with abnormal nail fold capillaries are sufficient 
to diagnosis early SSc
51
. 
Recently EULAR European League against Rheumatism 
Scleroderma Trial and Research Group
52
 proposed another set of 
criteria (Yet to be validated) for very early diagnosis of SSc in 
which there is central role for nailfold capillaroscopy in identifying 
early SSc. 
A study showed that reduced nailfold capillary density in SSc 
patients associated with established PAH, due to possible 
pathogenic significance and thus help in detection of this subset at 
an early stage. 
A recent study showed that there was strong association 
between higher capillaroscopic avascular scores and ground glass 
lung opacities, especially in SSc patient with <5 years disease 
duration
53
. 
Recent large study
54
 showed SSc patients with PAH had 
lower capillary density when compared with SSc patients without 
PAH, but loop dimensions were equal in both. The reduction in 
nailfold capillary density correlated with severity of PAH in SSc 
and idiopathic PAH. 
  31 
Widefiled microscopy is entirely non invasive method in 
which nailfold capillaries running parallel to epidermis can be 
examined under a light microscope with magnification of x12 
x14
55
. 
Nailfold video capillaroscopy(NVC) is an extension of the 
original widefield technique,with a videocamera connected to the 
microscope  with higher magnification.  
Cutola et al
56
 reclassified microvascular alteration into 3 
defined NVC patterns (early, active, late). 
There is association between capillary pattern and disease 
subtype and autoantibody status. 
PULMONARY MANIFESTATIONS 
Pulmonary disease is an important component of SSc with an 
estimate of 80% of SSc patients showing evidence of pulmonary 
involvement. 
It is the leading cause of death in SSc patients contributing 
33% to the mortality
57
. The common pulmonary manifestations of 
SSc are interstitial lung fibrosis and pulmonary hypertension while 
other pulmonary manifestations include pleural effusion, aspiration 
pneumonia, bronchiectasis, endobronchial telangiectasia with 
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hemoptysis, obstructive airway disease cryptogenic organizing 
pneumonia and lung neoplasms. 
Lung fibrosis occurs in both limited and diffuse cutaneous 
scleroderma, but is more commonly in diffuse subset. Though only 
40% of SSc patient have clinically evident ILD, autopsy findings 
reveal higher percentage of 80% prevalence, range from 25% to 
90% depending on the method used to identify pulmonary fibrosis. 
Pulmonary function tests defining restrictive lung disease by forced 
vital capacity <80% predicted value and FEV1 (forced expiratory 
volume in 1 second) identified 25% of ILD in a study with Danish 
patients
58
. 
On using higher resolution computed tomography (HRCT) 
prevalence of pulmonary fibrosis in patients with scleroderma was 
as high as 90% in 2 studies. 
PREVALENCE IN THE SUBSETS 
Using PFT restrictive pattern as marker of pulmonary fibrosis 
23% of limited subset and 40% of diffuse subtype had pulmonary 
fibrosis. 
By CXR, 33% of limited SSc and 40% of diffuse scleroderma 
had pulmonary fibrosis
59
. 
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Sken et al showed that the patients of diffuse SSc and CREST 
had similar PFT abnormalities
60
. 
In most patients, onset of pulmonary fibrosis occur within 
first 3 years of disease onset. After the occurrence of pulmonary 
fibrosis, greatest loss of lung volume occur within first two years
61
. 
Clinically symptoms of disease usually occurs in 55% of 
patients with ILD, whereas cough is dry, non productive and seen 
less commonly. Rarely hemoptysis can occur, but it may be 
complication of carcinoma or bronchial talengiectasia. Fine end 
inspiratory crackles of “velcro” character are heard at lung bases, 
while pleural rub is very rare. 
Esophageal reflux and dilatation was associated with 
pulmonary fibrosis. In a study, scleroderma patients with severe 
oesophageal motor dysfunctions on comparison with those with 
moderate or no oesophageal motor dysfunction, exhibited a higher 
prevalence of pulmonary fibrosis
62
. 
Progressive lung fibrosis proceeding to severe restrictive lung 
disease occurs only in a minority. The risk factors for the 
progressive nature include ethnic background (Black & Japanese 
races), diffuse cutaneous scleroderma and anti SCl70 positivity. 
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Patients with normal PFT at presentation time and stable lung 
function at follow up period are unlikely to go for severe 
pulmonary fibrosis,. Patient with low FVC and DLco values at 
baseline are likely to progress to end stage lung disease.  
Decline in DLco have been associated with male sex, severe 
Raynaud‟s Phenomenon and PHT. 
Anti topoisomerase-I (Anti SCl70) antibodies are associated 
with increased prevalence of pulmonary fibrosis in all patients, 
especially in diffuse type. The presence of DR3/ DRW52a anti 
SCl70 has a relative risk of 16.7 for occurrence of pulmonary 
fibrosis in scleroderma patients
63
. Anticentromere antibodies have a 
negative association with prevalence of pulmonary fibrosis.  
Chest radiography abnormality occurs in 25%-67% of SSc-
ILD patients. The typical reticular pattern in lung bases and 
periphery is seen in early disease. In advanced disease, there is loss 
of lung volume, more extensive reticular shadowing and honey 
combing. 
PULMONARY FUNCTION TESTING 
PFT is important for the evaluation of dyspnea and detection 
of pulmonary involvement in SSc patients. Patients with ILD 
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demonstrate restriction pattern, although in mild disease it may be 
normal. Total lung capacity by plethysmography is reliable method 
to confirm lung restriction, but it is a complex procedure. 
Spirometry is a simple test and measures static lung volumes at rest 
(vital capacity, forced vital capacity) and dynamic volumes (forced 
expiratory volume in 1 sec) in flow volume- loops. 
In restrictive lung disease, the FVC will be reduced and the 
ratio of FEV1/ FVC is normal.  
In scleroderma patients  FVC of less than 75% predicted 
value is seen in 40% patients indicating presence of ILD.  
The diffusing capacity of carbon monoxide (DLco) measures 
the gas transfer between the inhaled air in the alveoli to the red 
blood cells in the circulation. Decreased DLco value is seen in 70% 
of SSc patients, making it the earliest signal of lung disease. It 
correlates with the extent of disease by HRCT scan. It will be 
reduced both in ILD and PHT, to differentiate the cause, ratio of 
FVC/DLco is calculated. If the ratio of FVC/DLco is <1.4, it is 
parenchymal cause and ratio of >1.4 it is pulmonary vascular 
involvement. When both ILD and vascular involvement occurs, 
FVC % and DLco% both are reduced. 
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The methods used for measuring DLco are single breath 
method, steady state method and multiple inert gas technique. High 
resolution computed tomography are sensitive in detecting early 
pulmonary interstitial fibrosis and accurate in assessing the severity 
of lung involvement. 
The earliest change occur at the juxtrapleural, posterior and 
basilar portion of the lungs.  
The HRCT findings in scleroderma patients are ground glass 
opacities (defined as increased lung attenuation without 
architectural distortion), reticular linear opacities (architectural 
distortion with reticular intralobular interstitial thickening), traction 
bronchiectasis, subpleural and diffuse honeycombing, small 
nodules and parenchymal bands
64
.  
The most common HRCT pattern in SSc-ILD is 
predominantly ground glass opacity and pulmonary fibrosis 
consistent of NSIP pattern. 
Whereas honeycomb cystic changes, a marker of UIP (Usual 
Interstitial Pneumonia) is reported in 11% to 37% SSc-ILD 
patients
65
. Overlap (mixture) of UIP and NSIP patterns may occur 
in SSc-ILD. 
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There are criteria for scoring the extent and severity of ILD 
on the CT scans based on the relative proportion of GGO, 
reticulations and fibroisis by visual or computer based 
quantification method. In the visual scoring system
66
, lung is 
divided into three zones (Apex of lung to aortic arch, aortic arch to 
inferior pulmonary vein and inferior pulmonary veins to lung bases) 
and in each zone the extent of abnormality is scored on a scale of 0 -
4 (0-Absent, 1- 1:% to 25%, 2-26% to 50%, 3-51% to 75%, 4: 76%- 
100%). 
Recently simplified scoring system is suggested based on 
whether less or more than 25% of the lung is affected
67
. 
The fibrosis on HRCT scans in SSc-ILD patients has been 
used to predict the progression of fibrosis and response to the 
treatment. In a study SSc patients with more extensive disease 
involvement by HRCT (more than 20% of lung volume) had higher 
mortality and rapid decline in the lung function. 
In one study
68
, the extent of 4 HRCT patterns of ILD (GGO, 
reticular, homey comb and mixed) in each lobe were scored. In the 
HRCT scores, the inflammatory index (GGO and mixed scores) and 
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fibrosis index (reticular and honey comb scores) were found to 
correlate with abnormal lung function.  
BRONCHOALVEOLAR LAVAGE (BAL)  
It is a procedure in which physiological solution (normal 
saline, plasmalyte or normosol) is instilled into a specified area of 
lung parenchyma and the fluid is aspirated. The aspirate represents 
sampling of about 1% of all alveoli. Usually BAL cellularity having 
more than 3% to 5% neutrophils or >3% eosinophils of the total cell 
count is considered lung inflammation. 
Early studies showed granulocytosis on BAL has been 
associated with active alveolitis and increased risk of 
deterioration
69
. 
But recent studies have shown that elevated neutrophil count 
in BAL reflect the increased extent of disease involvement on CT, 
rather than the progression of the disease.  
In the scleroderma lung study, the data suggested that BAL 
granulocytosis did not give any additional prognostic information 
than the HRCT and PFT values and it was not a predictor of 
treatment response
70
. 
The role of BAL in ruling out infection is still important.  
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The histological subtypes by lung biopsy were similar to 
radiographic appearance in SSc-ILD. NSIP is the most common 
pattern seen in 76% of the cases in one study, while UIP seen in 
11% of the cases
71
. Rarely organizing pneumonia and diffuse 
alveolar damage occur. The survival rate did not differ between 
cellular NSIP, fibrotic NSIP and UIP pattern in a series of 80 
patients, indicating that histology has no prognostic value.  
PULMONARY HYPERTENSION 
Pulmonary arterial hypertension (PAH) is a devastating 
vascular complication in systemic sclerosis. Inspite of advances in 
early diagnosis and newer treatment, SSc- related PAH is a leading 
cause of mortality
72
. The mean pulmonary arterial pressure of more 
than 25mm Hg with a pulmonary capillary wedge pressure 
<15mmHg by right sided heart catheterization is a definite 
diagnosis of pulmonary hypertension
73
. 
It is mainly due to an occulusive vasculopathy of the 
pulmonary arterial system leading to increased resistance to 
pulmonary blood flow with elevated pulmonary pressures.  The 
prevalence of SSc-PAH is 7.8 to 12% in prospective studies, while 
French registry accounted for 15.3%. 
  40 
Clinical markers for the increased risk of developing PAH in 
SSc are limited cutaneous type, disease duration greater than 3 
years,the  age of onset of SSc, severity or duration of Raynaud 
Phenomenon, reduced nailfold capillary density and prominent 
telangiectasia
74
. Serological markers like ACA and antifibrallin 
antibodies, increase risk of SSc associated PAH. 
Isolated reduction of DLco or progressive decrease of DLco 
is emphasized as an independent predictor of PAH, especially in 
SSc-PAH. 
The gold standard for determining PAH in SSc patients is 
right heart catheterization enabling to quantify the response of 
pulmonary vessels to vasodialators and guide in the treatment. 
However Doppler echocardiography is useful as an effective 
and non invasive method to assess the presence and severity of 
PAH and exclude myocardial or valvular abnormalities. 
Doppler echocardiography can be provide a better indication 
of PAH presence, if the peak velocity of tricuspid regurgitation is 
assessed. The maximum velocity of the regurgitation jet of the 
tricuspid valve into the right atrium during ventricular systole is an 
estimate of right ventricular systolic pressure. The contribution of 
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elevated echocardiographic systolic PAP along with an elevated 
right ventricular Tei-index is more reliable indication of PAH
75
. 
The applications of either of the two approaches will 
minimize the negative cardiac catheterization. 
All SSc patients should be annually screened for the presence 
of PAH by Doppler echocardiogram .Studies shows that the 8% of 
SSc patients had PAH at 5 years from the onset of disease and 12% 
may ultimately be affected in the later disease. 
The limitation of Doppler echocardiograph is the rate of false 
positive or false negative is nearly 30% in the important range of 
30 to 50 mmHg of pulmonary artery pressure. 
The 6 minute walk test is non invasive method used for assessing the 
dyspnea severity in CTD related PAH. It is recommended as baseline 
assessment and to monitor response to therapy in idiopathic PAH and not 
indepently validated in SSc-PAH
76
. In metaanalysis of involving treatment 
with bosentan and sildenafil in IPAH and SSc-PAH, there was significant 
improvement in 6MWD in IPAH and not in SSc PAH patients. In 6MWT 
requires a integrated response of system needed for daily functioning, so 
comorbidities like pain and musculoskeletal dysfunction reduce the 
reliability and validating of this test in SSc patients
77
.  
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MATERIALS AND METHODS 
SUBJECTS 
Patients attending the Rheumatology Care Centre (RCC) 
outpatient and inpatient of Rajiv Gandhi Government General 
Hospital, Chennai were recruited from the period of June 2011 to 
February  2013. 55 eligible cases who fulfilled the inclusion criteria 
were enrolled. All subjects gave a written informed consent to 
enroll in this study. The Ethical committee approval was obtained. 
INCLUSION CRITERIA 
American College of Rheumatology preliminary classification 
criteria. 
Major criteria or two minor criteria for diagnosis.  
Major criteria 
Scleroderma proximal to the metacarpophalangeal joints. 
Minor Criteria 
1. Sclerodactyly. 
2. Digital pitting scars or loss of finger pad substance. 
3. Bibasilar pulmonary fibrosis. 
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EXCLUSION CRITERIA 
Overlap syndrome, mixed connective tissue disease, other 
scleroderma spectrum disorders. 
CLINICAL AND LABORATORY ASSESSMENT 
Detailed history, physical examination and evaluation were 
done in all patients. Laboratory evaluations including complete 
hemogram, liver function tests, renal function tests, blood sugar 
and lipid profile were done. Immunological assays consisting of 
CRP (Latex agglutination methods), ANA (ELSIA/ Hep2) and ENA 
profile were done. 
Other investigations like ECG, Chest X-ray, USG abdomen 
was done. HRCT chest using Siemens 4 slice CT scanner with 1mm 
cut was taken for all the patients. 
The extent and severity of skin tightening was recorded with 
modified Rodnan skin scoring. 
PULMONARY FUNCTION TESTS 
All cases were subjected to spirometry. The patient are asked to 
blow maximum after deep inhalation and restrictive pattern was 
interpreted if the ratio FEV1/ FVC was normal (>70%) with reduced 
FVC <80% (forced vital capacity) using peak expiratory flow meter.  
  44 
Diffusion capacity for carbon monoxide (DLco) was done by 
single breath method. The test gas is a composition of mixture 
(0.3% Co, 0.3% methane and 21% oxygen). The patient inspires the 
test gas deeply in less than 4 seconds and after holding the breath 
for 10 seconds he exhales to the maximum within 4 seconds. Value 
of <80% is considered decreased. 46 patients underwent DLco. 
Medsger‟s severity scale (appendix-1) which is a disease 
severity scale for 9 organ system with a score of 0 to 4 applied for 
skin and lung. (0-Normal, 1-Mild, 2-Moderate, 3- Severe and 4- 
end stage). This scale was used for the skin and lung to measure the 
severity and damage.    
Skin Biopsy 
Under local anaesthesia, incisional skin biopsy from the 
sclerotic lesion was done for the study cases. 
Bronchoalveolar Lavage  
In this procedure 100ml of normal saline was instilled 
through bronchoscope and 2/3
rd
 of the fluid was aspirated back by 
slow suction and sent for analysis.It was done for 26 cases. 
ECHOCARDIOGRAM 
2D Echocardiogram was done for all the study cases and 
pulmonary hypertension was detected by the presence of tricuspid 
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regurgitant peak gradient (TRPG) of >25 mmHg and graded as mild 
(<40mmHg), moderate (40-60mmHg) and severe (>60mmHg). 
STATISTICAL ANALYSIS 
The statistical analysis was performed using the SPSS 
(Version 11.5). Frequencies are expressed as percentages and other 
results as mean and standard deviation (SD). 
Paired „t‟ test, one way anova test and Pearson  chisquare test 
was used in this study.  P value less than 0.05 was considered 
statistically significant. 
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RESULTS 
Total number of cases were 55. 
The mean age was 35.5 years. The range was from 20-56 
years. 
Table-1: Age Distribution 
Age in years Frequency Percent 
20-30 20 36.4 
31-40 20 36.4 
41-50 13 23.6 
Above 50 2 3.6 
Total 55 100.0 
Figure -1: Age Distribution 
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Majority were females 49 (89.1%) while males were 6 
(10.9%). 
Table-2: Sex Distribution 
Gender Frequency Percent 
Male 6 10.9 
Female 49 89.1 
Total 55 100.0 
 
Figure-2: Sex Distribution 
11%
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The mean disease duration was 3.1 years with range 4 months 
to 10 years. 
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CLINICAL CHARACTERISTICS OF CASES 
Limited cutaneous disease was observed in 32 (58.2%) and diffuse 
cutaneous disease subsets were 23 (41.8%). The MRSS ranges was 4-30 
and the mean MRSS was 11.87. Out of 55 patients 16 (29.1%) revealed 
MRSS <6  and  24 (43.6%) had MRSS 7-15. In the MRSS range of 16-21 
and >21, there was 7 (12.7%) and 8 (14.5%) patients respectively. 
Table-3: Distribution of MRSS 
MRSS Frequency Percent 
< 6 16 29.1 
7-15 24 43.6 
16-21 7 12.7 
>21 8 14.5 
Total 55 100.0 
Figure-3: Distribution of MRSS 
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Salt and pepper was noted in 38 (69.1%) Digital ulcers was 
observed in 13 (23.6%). Digital pitted scars were seen in 
32(58.2%). Gangrene of digits was observed in 8 (14.5%). 
Raynaud‟s Phenomenon was seen in 47 (85.5%) cases.  
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Table-4: HRCT Lung 
HRCT Lung Frequency Percent 
No ILD 18 32.7 
ILD NSIP 25 45.5 
ILD UIP 9 16.4 
ILD both 3 5.5 
Total 55 100.0 
Pulmonary involvement was noted in39 (70.9%). By HRCT 
Chest, ILD was seen in 37 cases (67.3%).  
In the patients with ILD, NSIP pattern was seen in 25 
(45.5%), UIP pattern seen in 9 (16.4%) and both pattern together in 
3 (5.5%). Pneumonitis was seen in 1 (1.8%) case. 
Table-5: Pulmonary Hypertension by ECHO 
Pulmonary Hypertension Frequency Percent 
Absent 47 85.4 
Mild 2 3.6 
Moderate 3 5.5 
Severe 3 5.5 
Total 55 100.0 
Pulmonary Hypertension was seen in 8 (14.5%). Both PHT 
and ILD was seen in 7 (87.5%) cases while isolated PHT seen in 1 
(12.5%) cases.  
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Dyspnea was seen in 39 (70.9%) patients. 
Decreased pulmonary function by PFT was seen in 42(76.4%) 
cases. Restrictive pattern was seen in 34 (61%) cases. 
Decreased DLco seen in 28(63%) of 46cases. 
Evidence of ILD by Chest X-Ray was seen in 24 (43.6%) cases. 
ANA was positive in 44 (80%) cases. 
SCL 70 was positive only in 4 (18%) of 23cases. 
Skin biopsy evidence of early changes were seen in 9(16.4%) 
cases and late fibrotic changes seen in 46 (83.6%) cases. 
Abnormal BAL changes were seen in 9(24.3%) cases of 37 patients. 
ECG changes (non specific ST changes, T inversion) seen in 
12 cases. 
Table-6: Medsger disease severity scale for lung  
Medsger disease severity Frequency Percent 
Normal 15 27.3 
Mild 23 41.8 
Moderate 15 27.3 
Severe 2 3.6 
Total 55 100.0 
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Table-7: Relation of the skin and pulmonary variables to MRSS and 
the percentage of the variables in the different MRSS frequency  
Variables MRSS Total P Value 
<6 7-15 16-21 >21 
Mean 
Disease 
Duration 
16 24 7 8 55 
P=0.821 
Subtypes 
LC 16(50%) 16(50%) 0 0 32 
P=0.000** 
DC 0 8(34.8%) 7(30.4%) 8(34.8%) 23 
Salt & Pepper 
Present 5 
(13.2%) 
18 
(47.4%) 
7 
(18.4%) 
8 
(21.1%) 
38 
P=0.000** 
Absent 11 
(64.7%) 
6 
(35.3%) 
0 
(0%) 
0 
(0%) 
17 
Digital Ulcer 
Present 5 
(38.5%) 
5 
(38.5%) 
23 
(15.4%) 
1 
(7.7%) 
34 
P=0.400 
Absent 11 
(26.2%) 
19 
(45.2%) 
5 
(11.9%) 
7 
(16.7%) 
42 
Digital Pitted Scars 
Present 8 
(25.0%) 
12 
(37.5%) 
5 
(15.6%) 
7 
(21.5%) 
32 
P=0.059 
Absent 8 
(34.8%) 
12 
(52.2%) 
2 (8.7%) 1 (4.3%) 23 
Gangrene 
Present 4 
(50.0%) 
1 
(12.5%) 
2 
(25.0%) 
1 
(12.5%) 
8 
P=0.202 
Absent 12 
(25.5%) 
23 
(48.9%) 
5 
(10.6%) 
7 
(14.9%) 
47 
MRSS was significantly associated with the sub types of limited 
and diffuse SSc and presence of salt and pepper.  No association seen 
between the disease duration, digital ulcers, digital pitted scars and 
gangrene with MRSS. 
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Figure-4: Relation of the SSc Subtypes to MRSS and the percentage of 
the variables in the different MRSS frequency 
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Figure-5: Relation of the Salt and pepper presence to MRSS and the 
percentage of the variable in the different MRSS frequency  
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Table-8: Relation of the pulmonary variables to MRSS and the 
percentage of the variables in the different MRSS frequency  
Variables 
MRSS 
Total P Value 
<6 7-15 16-21 >21 
Dyspnea 
Present 10 
(25.6%) 
15 
(38.5%) 
6 
(15.4%) 
8 
(20.5%) 
39 
P=0.015* 
Absent 6(37.5%) 9(56.3%) 1(6.3%) 0(0%) 16 
Pulmonary Hypertension 
Present 3 
(38.5%) 
3 
(38.5%) 
1 
(12.5%) 
1 
(12.5%) 
8 
P=0.374 
Absent 13 
(28.3%) 
21 
(48.7%) 
6 
(11.9%) 
7 
(15.2%) 
47 
ILD by HRCT 
Present 10 
(27.0%) 
15 
(40.5%) 
6 
(16.2%) 
6 
(16.2%) 
37 
P=0.050* 
Absent 6 
(33.3%) 
9 
(50.0%) 
1 (5.6%) 2 
(11.1%) 
18 
PFT  
Reduced 10 
(27.0%) 
18 
(42.9%) 
7 
(16.7%) 
7 
(16.7%) 
42 
P=0.217 
Normal 6 
(46.2%) 
6 
(46.2%) 
0  
(0%) 
1 (7.7%) 13 
Disease Severity of Lung 
Present 10(25%) 16(40%) 7(17.5%) 7(17.5%) 40 
P=0.025* Absent 6 
(40.0%) 
8 
(53.3%) 
0 (0%) 1 (3.0%) 15 
MRSS was significantly associated with dyspnea, ILD and 
Medsger disease severity score of lung. No association seen 
between pulmonary hypertension, reduced PFT with MRSS. 
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Figure-6: Relation of ILD to MRSS and the percentage of the 
variables in the different MRSS frequency 
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Figure-7: Relation of PHT to MRSS and the percentage of the 
variables in the different MRSS frequency 
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LIMITED CUTANEOUS SYSTEMIC SCLEROSIS RELATION 
BETWEEN THE MEAN MRSS AND PULMONARY 
VARIABLES 
Table-9: Relation between the mean MRSS and ILD 
ILD N Mean Std. Deviation P-Value 
Absent 14 7.21 2.424 
P=0.463 
ILD NISIP 12 6.92 3.343 
ILD UIP 5 8.60 2.408 
ILD both 1 4.00 – 
Total 32 7.22 2.802 
Table-10: Relation between the mean MRSS and PFT 
PFT  N Mean Std. Deviation P-Value 
Normal 11 6.55 2.018 
P=0.333 
Reduced 21 7.57 3.124 
Table-11: Relation between the mean MRSS and PHT  
 N Mean Std. Deviation P-Value 
Normal 13 7.00 2.380 
P=0.808 
Mild 13 7.62 3.042 
Moderate 6 6.83 3.488 
Total 32 7.22 2.802 
No association seen between the mean MRSS and ILD, PHT 
reduced PFT in limited cutaneous subtype.  
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Figure-8: Limited cutaneous Systemic Sclerosis relation between the mean MRSS and Pulmonary Variables  
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DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS RELATION 
BETWEEN THE MEAN MRSS AND PULMONARY 
VARIABLES 
Table-12: Relation between the mean MRSS and ILD 
ILD N Mean 
Std. 
Deviation 
P-Value 
Normal 4 20.75 7.455 
P=0.046* 
ILD NISIP 13 19.38 6.063 
ILD UIP 4 12.00 3.651 
ILD both 2 19.50 2.121 
Total 23 18.35 6.228 
Table-13: Relation between the mean MRSS and PFT 
PFT  N Mean Std. Deviation P Value 
Normal 2 17.50 7.778 
P=0.846 
Reduced 21 18.43 6.289 
Table-14:Relation between the mean MRSS and PHT 
PHT N Mean Std. Deviation 
Absent 19 37.06 . 
Mild 1 10.00 . 
Moderate 3 17.00 7.810 
Total 23 18.35 6.228 
Significant association present between mean MRSS and ILD 
in the diffuse cutaneous type. There was no association with the 
mean MRSS with PHT and reduced PFT.  
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Figure-9: Diffuse cutaneous Systemic Sclerosis relation between the mean MRSS and Pulmonary Variables  
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Table-15: Digital Ulcer association with pulmonary variables  
Variables N 
Pearson Chi-Square 
Value 
df 
P-
Value 
ILD 
Present 3 (23.1%) 
0.914 
3 0.822 
Absent 10(76.9%) 
PHT 
Absent 12(92.3%)%) 
5.860 
4 0.210 
Present 1 (7.7%) 
PFT 
Normal 3 (23.1%) 
0.003 (b) 
1 0.637 
Reduced 10 (76.9%) 
Figure-10: Digital Ulcer association with pulmonary variables 
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No association seen between digital ulcer and pulmonary 
variables. 
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Table-16: Salt and Pepper association with pulmonary variables  
Variables N Pearson Chi-Square Value df P-Value 
ILD 
Absent 12 (31.6%) 
0.182 (a) 3 0.980 
Present 26 (66.4% 
PHT 
Absent 34 (86.8%) 
8.207 4 0.084 
Present 4 (10.2% 
PFT 
Normal 8 (21.1%) 
0.455 1 0.363 
Reduced 30 (78.9%) 
Presence of salt and pepper was not associated with 
pulmonary variables. 
Table-17: Digital Gangrene association with pulmonary variables 
Variables N Pearson Chi-Square Value df P-Value 
ILD 
Absent 2 (25.0%) 
1.365 (a) 3 0.714 
Present 6 (75.0%) 
PHT 
Absent 8 (100%) 
1.832 4 0.767 
Present 0 (0%) 
PFT 
Normal 2 (25%) 
0.010 (b) 1 0.922 
Reduced 6 (75%) 
Digital gangrene was not associated with pulmonary 
variables. 
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Table-18: Digital Pitted Scar association with pulmonary variables 
Variables N Pearson Chi-Square Value df P-Value 
ILD 
Absent 5 (15.6%) 
12.823 (a) 3 0.006* 
Present 27 (84.4%) 
PHT 
Absent 29 (90.6%) 
2.433 (a) 4 0.657 
Present 3 (9.4%) 
PFT 
Normal 5 (15.6%) 
2.721 1 0.099 
Reduced 27 (84.4%) 
Figure-11: Digital Pitted Scar association with pulmonary variables  
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Digital pitted scars was significantly associated with ILD. It 
did not correlate with PHT and reduced PFT. 
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Table-19: Raynaud’s Phenomenon association with pulmonary 
variables 
Variables N Pearson Chi-Square Value df P-Value 
ILD 
Absent 12 (25.5%) 
7.944 (a) 3 0.047* 
Present 35 (74.5%) 
PHT 
Absent 39 (80.9%) 
1.832 (a) 4 0.767 
Present 8 (19.1%) 
PFT 
Normal 9 (19.1%) 
3.605 (b) 1 0.058 
Reduced 38 (80.9%) 
Raynauds Phenomenon was significantly associated with ILD. 
But there was no association with PHT and reduced PFT. 
Table-20: Disease duration with pulmonary variables 
Variables N Mean S.D P.Value 
ILD 
Absent 18 3.328 2.728 
0.901 
Present 37 3.104 2.218 
PHT 
Absent 47 3.291 2.530 
0.032* 
Present 8 3.000 1.732 
PFT 
Normal 13 3.321 2.624 
0.3867 
Reduced 42 3.112 2.506 
Disease duration significantly correlated with the PHT. No 
correlation present between ILD, decreased PFT and disease 
duration. 
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DISCUSSION 
In our study, out of the total 55 cases there was a female 
gender predominance 89.1% with males only 10.9%. Similar to this 
study G.C.Kane et al
77
 in their study observed females of 86% and 
males 14%. 
In this study, there was increased frequency of limited 
cutaneous subtype 32 (58.2%) than the diffuse cutaneous type 23 
(41.8%). This was in concurrence with study by Geirsson A J et al
78
 
with limited and diffuse subtypes of 62% and 38% respectively.  
Whereas Ostogic P et al
79
 and Terry A. et al
80
 showed in their 
studies diffuse cutaneous type of higher frequency of 58% and 
55.6% respectively.  
In this study, the median MRSS was 11.8%. Out of the 55 
patients 24 (43.6%) were in the 7-15 MRSS range. Similar to this, 
study by L.G.Hanitsch et al
81
 found 58.6% of the patients in the 6-
14 MRSS Range. 
In our study, pulmonary involvement was seen in 39 cases 
(70.9%) with ILD by HRCT Chest present in 37 (67.3%) patients. 
Within the ILD, NSIP pattern 25 (45.5%) was more common than UIP 
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pattern 9 (16.4%). Similar to this Arroliga et al
82
 in their study there 
was CT evidence of pulmonary fibrosis in 65% of SSc patients. 
In a study by Sergio Fernandes et al
83 
with 58 SSc patients, 51.7% 
presented ILD by HRCT Chest whereas ILD by CT scan was seen in 
86.7% patients in a study with 45 SSc patients by Ooi GC et al. 
Studies by Bouros et al
84
 and Veeraraghavan et al
66
 showed 
NSIP pattern was the most prevalent than UIP pattern in SSc 
associated ILD and NSIP had better prognosis. 
In our study, significant association was seen between the 
MRSS and ILD in the total cases. In the subtypes there was 
significant association between the mean MRSS and ILD in the 
diffuse cutaneous type.  
Similar to our study L.G.Hanitsch et al
81
 showed that higher 
MRSS was associated with pulmonary fibrosis, digital ulcers and 
dysphagia in 1483 SSc patients of the German Network registry. 
In our study ILD was present in 18 (56%) of limited 
cutaneous subtype and in 19 (82.6%) of diffuse type which was 
similar to the study by UA Walker et al,  in a meta analysis  the 
occurrence of pulmonary fibrosis was more common in DcSSc 
53.4% than limited cutaneous 34.7%
27
. 
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Similarly, Simeon- Aznar et al
85
, in the study with 916 Spanish 
SSc patients, ILD was more frequent in the DcSSc than LcSSc 
subsets. 
Whereas in the study by Kane GC et al, there was no 
difference in the pulmonary involvement in the two subtypes
77
. 
A study by Perera A et al
86
 in 212 SSc patients ILD was 
common and equally present in the diffuse and limited subtypes. 
The mean MRSS in both limited and diffuse sub types did not 
correlate with the pulmonary hypertension and reduced pulmonary 
function. 
CXR evidence of ILD was seen in 24 (43.6%) which was 
similar to the study by Owens G.R. et al with chest X-ray showing 
pulmonary fibrosis was seen in 40% of the scleroderma patients
59
. 
Dyspnea was seen in 39 (70.9%) of the cases which was 
similar to the study by Sergio Fernandes et al
83
 were 65.5% of SSc 
patients had dyspnea.  
Decreased pulmonary function was seen in 42 (76.4%) cases 
in this study. Similar to this study by Owens et al reported 72% of 
88 scleroderma patients had decreased pulmonary function.  
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In a study by Wells A U et al showed 70% of SSc patients 
with decreased pulmonary function
87
. 
In this study the disease duration was significantly associated 
with pulmonary hypertension but there was no association with ILD 
or reduced PFT.  
Similarly in a study by Jerome et al.,
88
 increased disease 
duration was seen in the development of PAH especially in the 
limited cutaneous type. Studies by Griedinger EL et  al
89
 and Steen 
VD et al
61
 observed that the onset of pulmonary fibrosis occurred 
with in the first three years of disease onset in majority of the 
patients. 
In this study PHT was seen in 14.5% similar to the study by 
Serigo Fernandes et al in which PAH prevalence was seen in 15.3% 
of the study population
83
. 
The MRSS was associated with Medsger lung severity score 
in this study. Similarly Steen and Medsger et al
34
 found MRSS 
correlated with disease severity of organs, especially in the dcSSc. 
By BAL, granulocytosis was seen in 9 (23%) of the 36 cases.  
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Salt and pepper was seen in 38 (69.1%) cases and there was 
significant association between the MRSS and presence of salt and 
pepper. Similar to our study, study by Ashish singh et al
90
 found 
that the salt and pepper appearance was seen in 15 out of 16 
scleroderma patients and it was a useful marker for early diagnosis 
of Systemic sclerosis patients. 
In a study done in Nigeria by Adelowo OO et al
91
, salt and 
pepper was a common presentation of the skin and it was associated 
with skin thickening. 
In another study by Sharma VK et al
92
, 51% of SSc patients 
had salt and pepper, which was associated with progressive 
sclerosis. 
In this study digital pitted scars were seen in 32 (58.2%) and 
digital ulcer seen in 13 (23.6%) and there was significant 
association between digital pitted scars and ILD. There was no 
association between the digital pitted scars and digital ulcers with 
pulmonary hypertension and reduced PFT. No association was seen 
between digital ulcers and ILD in this study. 
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Similar to this study Sarit Khimdas et al
93
 in a study on 938 
SSc patients observed digital pitting scars in 53.1% and digital 
ulcers in 34.1% in the cases. 
In their study the digital ulcers and digital pitting scars were 
associated with ILD, increased MRSS and higher HAQ score.  
In another study by Maeda et al
47
 digital pitted scars were 
found in 39% of 87 SSc patients and were associated with skin 
thickening, Raynauds Phenomenon and joint disease. 
Manoussakis MD et al
94
 in their study of 34 SSc patients 
showed the presence of digital pitting scars correlated with 
impaired pulmonary diffusion and ILD, suggesting that the 
interstitial pulmonary disease in systemic sclerosis is secondary to 
vascular pathology  like digital pitted scars. 
Digital gangrene was seen in 8 (14.5%) in this study, whereas 
the study by Sarit Khimdas et al observed only 1.8% of digital 
gangrene in their study group
93
. 
In our study, Raynauds Phenomenon was seen in 47 (85.5%) 
and there was association with ILD suggesting vascular pathology 
in ILD. There was no association between Raynauds phenomenon 
and pulmonary hypertension or reduced PFT.  
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The skin biopsy showed early skin lesions in 16% and late 
fibrotic changes in 83% cases. Study by Frust De et al showed the 
MRSS as an accurate reflection of the skin biopsy changes and so 
in this study MRSS was used for correlation
35
. 
In this study ANA was positive in 44 (80%) cases. As per 
literature >95% patients of SSc present with autoantibodies. Similar 
to our study, R.Hesselstrand et al
95
 in their study of 276 SSc 
patients 84% were ANA positive. 
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CONCLUSION 
 In this study on Systemic sclerosis there was a female gender 
predominance(8:1). 
 The limited cutaneous SSc were more than diffuse cutaneous 
type in this study. 
 There was positive correlation between disease duration and 
PHT. 
  43.6% of the study group were in the 7-15 MRSS Range. 
 Presence of salt and pepper had significant association with 
MRSS in this study. 
 Dyspnea was the most common respiratory symptom and it 
correlated positively with MRSS. 
 The MRSS was significantly associated with presence of ILD 
in the study group. 
 ILD was more common in diffuse cutaneous type and  the mean 
MRSS was significantly associated with ILD in diffuse 
cutaneous type. 
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 There was no association between MRSS and PHT in this 
study. 
 There was significant association between MRSS and the 
Medsger disease severity of lung. 
 Digital pitted scars and Raynaud‟s Phenomenon positively 
correlated with ILD in this study group. 
 ANA positivity was seen in 80% of the cases. 
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characterized by significant dysfunction of the microvasculature, immune system and connective
tissue. The currently used classification of Systemic Sclerosis is by the extent of skin involvement1.
The extent of skin disease correlates with the disease course. Though many internal organs are
involved, lung involvement is major cause of morbidity and mortality in SSC. While some studies
regard skin involvement as a surrogate marker for pulmonary...
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